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Reduced growth of dermal fibroblasts 
from chronic venous ulcers can be 
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Vladimir Russakovsky, BS, and James O. Menzoian, MD, Boston, Mass. 
Purpose: Although the slow healing rate of venous ulcers is well known, the underlying 
defect in the healing process is not well understood. The purpose of this study was to 
examine the cellular characteristics of fibroblasts taken from venous ulcers (wound-fla) 
and compare them with the fibroblasts of normal tissue (normal-fb). 
Methods: Biopsy specimens were obtained from wound margins and normal tissue of the 
upper thigh in each patient. Dermal fibroblasts were isolated from explant cultures in 
Dulbecco's modified Eagle's medium supplemented with 10% calf serum. These cells were 
then plated at 1000 cells per plate, and total cells per plate were counted over time so that 
growth curves could be generated. In further experimentation, media was supplemented 
with additional calf serum (20%, 30%, 40%, 50%) and growth factors (epidermal growth 
factor, basic fibroblast growth factor, interleukin-l[~) in an attempt to stimulate growth. 
Results: Two major differences were noted: (1) normal-fla replicated more rapidly than 
wound-fla; and (2) the morphologic features ofwound-fb were different. Normal-fla were 
compact and tapered, with well-defined nuclear morphologic features. Wound-fla were 
larger and polygonal in shape, with less-uniform nudear morphologic features. Addi- 
tional calf serum in tissue culture media enhanced normal-fla growth but had no effect on 
wound-fla. Supplementation f media with growth factors stimulated the growth of 
wound-fla. Statistically significant differences were noted at day 10 and 14 with basic 
fibroblast growth factor supplementation (p = 0.02 and 0.0001, respectively) and at day 
14 with epidermal growth factor (p = 0.008). Although interleukin-l[~ stimulated cell 
growth in five of six patients, the differences observed were not statistically significant. 
Conclusions: Our data demonstrate hat wound-fla proliferate at a slower rate and are 
morphologically distinct from normal-fla. These characteristics are typical of aged or 
senescent cells. This decreased growth can be stimulated by growth factors basic fibro- 
blast growth factor, epidermal growth factor, and interleukin- 16. Slowed growth may be 
partially responsible for the defect in healing of venous stasis ulcers. Furthermore, we 
believe that in some patients ulcer healing may be improved by exogenous provision of 
specific growth factors. (J Vasc Surg 1997;26:994-1001.) 
Substantial resources are directed each year to- 
ward the treatment of venous ulcers. Numerous epi- 
demiologic studies have commented on the chronic- 
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ity of  the ulcers as well as their tendency to recur. 
Population studies have identified venous insuffi- 
ciency as the cause of 70% of leg ulcers? ,2 In a recent 
Swedish study, the prevalence of open venous ulcer- 
ations was 0.16% of the population. In the same 
study, 70% of the ulcers were recurrent. Ulcers re- 
quired therapy for longer than a year in 54% of the 
patients? The cost and manpower required to care 
for these wounds is staggering. In a longitudinal 
study, 25 outpatients were studied to calculate the 
cost of outpatient care and determine use of re- 
sources. An average of 27 visits to the home per 
month were made by skilled health workers, and an 
overall cost was calculated to be $1900 per month. 
This cost does not include physician visits or inpa- 
tient charges. 4 
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Despite the prevalence, cost, and morbidity of 
venous ulcers, treatment has not changed signifi- 
candy in recent years. Compression bandages and a 
variety of dressings remain the mainstay of therapy. 
Adhesion molecules and conditions within the 
wound environment are two areas of ongoing re- 
search that have yet to affect the clinical arena. 
Growth factor therapy has emerged in recent years as 
an experimental tool in wound repair. Several clinical 
studies have found growth factors (epidermal growth 
factor [EGF] 5 and interleukin [IL]-I[3 6, amongst 
others) to be of some help in the healing of wounds, 
whereas others have found evidence to the contrary. 7 
Growth factor therapy in venous ulcers has not 
proven to be an effective mode of therapy in early 
clinical trials, s
The wound repair process within chronic venous 
ulcers is ineffective. Normal tissue integrity is not 
reestablished for extended periods of time after in- 
jury. In this study we examined fibroblasts taken 
from patients with venous ulcers (wound-fb) and 
compared them with fibroblasts taken from unin- 
volved dermal tissue of the thigh (normal-fb). The 
fibroblast is a cell type that is important to all stages 
x 
of wound repair. Initially, fibroblasts must migrate to 
and proliferate in the wound. They must also re- 
spond appropriately to cytoldnes and other factors 
that modulate and direct the production of extracel- 
lular matrix and the process of wound contracture. 
Healthy, functioning fibroblasts are necessary for ex- 
pedient wound healing. In this study we demonstrate 
differences between populations of wound-fb and 
normal-fb that may help to identify the healing de- 
fect found in venous ulcers. 
PATIENTS AND M_ETHODS 
Patients with chronic venous ulcers were inter- 
viewed and examined. Eight patients agreed to enroll 
in the study. Tissue cultures of two patients eventu- 
ally became contaminated before we could complete 
testing. Six patients completed all phases of the 
study. 
Evaluation of the severity of venous disease in 
enrolled patients was determined using the guide- 
lines prepared by the Executive Committee of the 
American Venous Forum (Clinical Classification and 
Grading of Chronic Venous Disease). 9 Patients in 
whom concomitant arterial disease was suspected as 
evidenced by absent pulses were excluded from the 
study. Patients who were taking immunosuppressives 
were excluded from the study. All patients with dia- 
betes, patients with known HIV-positive status, and 
patients with active infection were excluded. After 
informed consent, one 4 mm punch biopsy was ob- 
tained from (1) uninvolved dermal tissue of the 
thigh; and (2) wound tissue tal~en from the border of 
the ulcer. This study was approved by the Institu- 
tional Review Board at Boston Medical Center. 
-Biopsies were treated with a 5-minute povidone- 
iodine bath followed by a 5-minute bath in 70% 
ethanol. Overnight trypsinization was then per- 
formed at 4 ° C (trypsin solution = 1 ~g/ml). The 
following day the specimens were incubated to 
37 ° C for 2 hours in the same trypsin solution. The 
trypsinization process facilitated separation of the 
dermal tissue from the epidermal and adipose tissue, 
which was performed manually under sterile condi- 
tions. The dermal tissue was then morseled and 
placed in etched plastic tissue culture dishes (Fisher). 
Dulbecco's modified Eagle's media (DMEM) with 
10% calf serum (CS) was added to support the 
growth of cells. DMEM containing 10% CS was 
sterilized by filtering through a 20 ~m pore filter 
paper (Nalgene). An antibiotic cocktail (penicillin, 
methicillin, fungizole, streptomycin) was added to 
the media while the fibroblasts were in explant cul- 
ture. Media was changed once a week until the fibro- 
blasts grown from the explant issue reached 30% to 
50% confluence. At this point, cells were fed two 
times per week with the same media until the cell 
population reached 60% to 80% confluence. Light 
microscopy (at 100×) was used in monitoring cul- 
tures for contamination. Cells were then trypsinized 
from their plates and passed onto two plates. One 
plate was used for freezing and storage, whereas the 
other was used for experimentation. All growth 
curves were performed on passage 2 (P2) cells. 
To trypsinize the cells, media was aspirated off 
and cells were rinsed twice with phosphate-buffered 
saline solution (PBS). Trypsin (1 ixg/ml) was then 
added to cell populations for 1 minute. After this, 
they were resuspended in DMEM with 10% CS. Cell 
suspensions were then diluted 4:1 in balanced salt 
solution and counted on a Coulter counter. The 
concentration f cells in suspension were then deter- 
mined. 
To generate growth curves of normal-fb and 
wound-fb, each patient's wound-fb and normal-fo 
were plated out  in a series of 1000 cell per 35 mm 
culture dishes. Each series of plates was then sub- 
jected to different concentrations of CS, various 
growth factors, and conditioned media. Every 3 to 4 
days (days 6, 10, 14, 17, and 21), cell counts of two 
plates from each series were determined. Growth 
curves were determined by plotting these cell counts 
per plate over a 3-week period. 
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Fig. 1. A, Normal-lb. Note tapered cells with regular nuclear morphologic features. B, 
Wound-fb. Note polygonal cell shape with pleomorphic nuclei (original magnification, 100×; 
no stain). 
CS. Increasing concentrations of CS (10%, 20%, 
30%, 40%, and 50%) were added to the DMEM 
to stimulate wound-fb growth. Populations of 
wound-Po and normal-fb from each patient were 
treated with each concentration of CS. These cells 
were allowed to grow for 10 days before cell counts 
were obtained. The media was changed every 3 to 4 
days. Cell counts of plates of  wound-fb and nor- 
mal-fb were obtained on day 10 for all patients. 
Growth factors. Three growth factors were 
used, EGF, IL-1 [3, and basic fibroblast growth factor 
(bFGF). Each growth factor solution was sterilized 
and added to media. The final concentrations were 
EGF, 200 ng/ml;  bFGF, 100 ng/ml;  and IL-1 [3, 2.5 
ng/ml.  These concentrations were chosen because 
previous tudies had demonstrated biologic activity 
at similar concentrations of growth factor. 6,1°-12 
Here, again, each patient's wound-fb and normal-fb 
were plated in series of  35 mm tissue culture dishes. 
Each series was subject o a different growth factor, 
and growth curves were determined using the 
method previously mentioned. 
Condit ioned media. Media that had been fed 
to a confluent plate of  normal cells for 3 to 4 days was 
collected, filtered through a (Nalgene) 20 ~m filter 
paper to remove any suspended normal-fl~ and mixed 
1:1 with fresh DMEM with 10% CS. This media was 
used for our conditioned media experiments. A series 
of wound-fb plates were treated with this condi- 
tioned media, and growth curves were determined in
the method previously mentioned. 
All statistical analyses were conducted using anal- 
ysis of variance software as licensed to Boston Uni- 
versity. 
RESULTS 
Clinical evaluation of the six patients in the study 
was carried out using the American Venous Forum 
guidelines. The six patients in the study had a mean 
score of 13.5, with a range of 11 to 17 (minimum 
score, 0; maximum score, 18). 
Populations of wound-fb and normal-fl~ were 
generated via the above protocols. Routine moni- 
toring of  cells in culture using light microscopy 
identified morphologic differences between the two 
populations. Normal-fb were compact and tapered, 
with well-defined nuclear morphologic features. 
Wound-fb were larger and polygonal in shape, with 
less-uniform nuclear morphologic features (Fig. 1). 
Statistical significance was calculated in all cases 
mentioned with analysis of variance software. Variables 
examined were patient, day of growth, and cell type. 
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Fig. 2. Effect of growth factors on cultured venous ulcer wound-fb. All growth curves are 
graphically displayed; y axis, cells counted per plate; x axis, days in culture. All patients with 
normal-fb (closed square) growth plotted along with wound-fl~ (open square), wound-fb + EGF 
(closed circle), wound-fb + bFGF (triangle), and wound-fb + IL-l[3 (X). 
Growth curves. Growth curves demonstrated 
that the growth rate ofwound-tb cells was markedly 
suppressed in all patients (Fig. 2). The difference 
between growth rates of  normal and wound cells 
grown in standard DMEM with 10% CS media was 
highly significant by day 10 (p = 0.0076) as well as 
day 14 (p = 0.0001). 
Varying concentration o f  CS. Further supple- 
mentation of media with additional CS (media con- 
taining 20% to 50% CS) failed to augment growth of 
wound-fo but improved normal-fb response (Fig. 3), 
as expected. 
Growth  factors. Growth factor supplementa- 
tion with EGF and bFGF improved the growth rate 
of wound-fb in comparison with wound-fb not 
treated with growth factors. This difference reached 
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Fig. 3. Effect of varying nutrition on wound-rio and nor- 
mal-Po. Wound-rio and normal-fb cultured in varying con- 
centration of CS. All counts done at day 10. 
statistical significance by day 14 in all patients (p = 
0.0001 and 0.0081 for bFGF and EGF, respective- 
ly). Statistical significance was noted as early as day 
10 (p = 0.02) with bFGF supplementation. IL-1[3 
improved growth in five of six patients, but this 
finding was not statistically significant. In comparing 
the results of growth factor supplementation, we 
noted that bFGF significantly augmented the growth 
rate of wound-fla when compared with wound-fla 
treated with EGF (p = 0.04) and IL-l[3 (p = 0.002). 
In two cases, growth factor-supplemented media 
augmented growth of wound-fla so that they out- 
grew normal-fla cultured in standard media. In the 
remaining four patients, growth factor supplementa- 
tion improved growth rates of wound-fla popula- 
tions, but not to the point where it surpassed the 
growth rate ofnorrnal cells (Fig. 2). 
Morphologic features of the population of 
wound-fla treated with growth factors changed ur- 
ing growth factor therapy. As noted earlier, 
wound-fla have been observed to be larger and more 
polygonal with less-distinct nuclei when compared 
with normal cells (Fig. 1). After 3 weeks of growth 
factor therapy (this was observed with all three fac- 
tors examined in this study), the population of cells 
was similar in morphologic features to normal-fla. 
Condit ioned media. When wound-fla were 
treated with media conditioned by normal-fla from 
the same individual, there was no change in growth 
patterns. M1 morphologic features and growth rates 
ofwound-fla treated with conditioned media were no 
different from those ofwound-fla treated with stan- 
dard DMEM media. 
DISCUSSION 
The therapy for chronic venous ulcers has not 
changed significantly in decades. Compression dress- 
ings, sldn grafting, and sequential compression devices 
are the current gold standard of therapy for this disease. 
Part of the problem is that the pathophysiologic mech- 
anism of these ulcers has not been dearly defined. The 
fibrin cuff and white blood cell sequestration theories 
are two explanations for the primary defect in healing. 
Recent work has suggested that a rnacromolecular eak 
may be responsible for altered wound healing) 3 Our 
data demonstrate hat the fibroblasts taken from the 
border of these ulcers behave differently than those 
from unaffected tissue. Wound-fla proliferate at a slower 
rate and are morphologically distinct from normal-fla. 
These characteristics make them similar to terminally 
differentiated or senescent fibroblasts that have a larger 
cell size and macromolecular mass with cells locked in 
G1/S and unable to replicate. I4 Our study suggests 
that the population of fibroblasts at the site of venous 
ulcerations has been changed by venous hypertension, 
the chronic wound environment or some other un- 
known factor. 
Growth factor therapy has not been clearly 
proven to be of benefit in the treatment of venous 
ulcers. Randomized prospective studies have been 
performed on small patient populations with equivo- 
cal results. Falanga et al. 8 found that ulcer size could 
be influenced by EGF but found the clinical results of 
this trial to be less spectacular than initially anticipat- 
ed. 15 TGF-~ is a second factor that has been involved 
in randomized prospective trials with marginal clini- 
cal benefit) 6 Our in vitro studies how an improve- 
ment in growth rates of wound cells treated with 
growth factors. The extent of the improvement was 
variable from patient o patient. Two of the six pa- 
tients had populations of wound-fla that grew at a 
slow rate in standard media but outgrew normal-fla 
in the presence of growth factors. The remaining 
four patients had a statistically significant improve- 
ment in growth rates without surpassing the growth 
rate of normal-fla. These results suggest hat either 
slowed growth is reversible or that growth factors 
selectively enhance growth of cells with higher pro- 
liferative capacity. 
The Hayflick model of cellular aging was devel- 
oped with human fibroblasts. In this model neonatal 
fibroblasts undergo proliferation and passage 40 to 
60 times until they are no longer able to replicate) 7 
This point has been called cellular senescence. Using 
this model, it has been shown that cells become less 
responsive to growth factors as they proceed through 
higher passages and approach senescence. Further- 
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more,  it has been shown that this lack o f  responsive- 
ness in aged cells is a result o f  fewer receptors, lower 
b inding affinities of  growth factor receptors, and less- 
efficient internal ization o f  the growth factor-receptor 
complex. 11 Similar data have been generated with 
patients o f  varying age. 
In  our in vitro studies, we noted cell morphologic  
features and suppressed growth rates that are similar 
to those o f  senescent cells. Furthermore,  when 
growth factors were added to populat ions o f  wound 
cells, the morpholog ic  features of  the cells after factor 
therapy were more like those o f  normal-fie. Popula- 
tions o f  fibroblasts are heterogenous.  I t is possible 
that amongst  he wound cells are varying percentages 
o f  senescent cells. With  the addit ion of  growth fac- 
tors to the media, these normal-fie overgrow the 
senescent cells. The growth rate variabil ity we have 
observed may be a reflection o f  the percentage o f  
senescent cells in the wound-fie populat ion before 
growth factor therapy is initiated. 
This variabil ity in responsiveness to growth fac- 
tors suggests that there may be a subgroup of  pa- 
tients who have chronic venous ulcers that are more 
likely to respond to growth factor therapy. Our  study 
further shows that the process that suppresses the 
growth and alters the morpholog ic  features o f  the 
populat ion o fwound- fb  may be overcome (in vitro) 
by growth factors. 
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DISCUSSION 
Dr. K. Craig Kent (Boston, Mass.). This is a fascinat- 
ing study that provides us with greater insight as to why 
wound healing in patients with chronic venous tasis ulcers 
is so tremendously delayed. The magnitude of the problem 
provided by chronic venous tasis in terms of cost to society 
was well outlined by Dr. Stanley in his presentation. A 
clearer understanding of the pathophysiologic mechanism 
of this disease process will enable the design of interven- 
tions that could increase the rate of healing of these lesions. 
In tissue culture, Dr. Stanley has grown fibroblasts that 
were derived from stasis ulcers and found these cells to be 
grossly abnormal in terms of their morphologic features 
and abnormal also in terms of their potential to proliferate 
when compared with cells derived from normal sldn. 
This is a critically important study for several reasons. 
First, we are provided with new lmowledge about he patho- 
physiologic mechanism of chronic venous stasis ulcers. We 
have learned that the defect in healing may be related to 
senescence offibroblasts within these indolent ulcers. 
Mmost more importantly, Dr. Stanley has created for 
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us an in vitro model in which agonists that might enhance 
or inhibit wound healing can be evaluated. He postulates 
that agonists that can reverse the defect in proliferation i  
wound-derived fibroblasts might also have significant po- 
tential for enhancing wound healing in patients who have 
stasis ulcers. 
I have two questions for Dr. Stanley. First, you have 
shown that bFGF and EGF both enhance the proliferative 
rate in wound fibroblasts, whereas erum does not. Did 
FGF and EGF also enhance the proliferative rate of fibro- 
blasts derived from normal tissue? If so, did fibroblasts 
derived from wounds respond less well to growth factors 
than did fibr0blasts derived from normal tissues? A dimin- 
ished response of wound fibroblasts o these growth factors 
compared with that of normal fibroblasts might, contrary 
to your interpretation, be considered as a discouraging 
finding and an explanation asto why growth factors have 
been only marginally effective in increasing the rate of 
healing of stasis ulcerations. 
Despite this concern, the increase in the proliferative 
rate of wound fibroblasts that you observed after stimula- 
tion with bFGF is encouraging and would suggest hat 
growth factor treatment of venous tasis ulcers might be 
practically usefial. However, as you point out in your 
manuscript, the results for clinical trials have been at best 
equivocal. Do you have insight as to why the clinical results 
have not been more impressive? In clinical models, is there 
difficulty with access of the growth factors to the fibro- 
blasts? Could matrix proteins be sequestering growth ]?ac- 
tors and denying cellular access of these proteins? Is there a 
way of overcoming this problem? 
I very much appreciate the opportunity to discuss this 
very interesting manuscript, and I congratulate Dr. Stanley 
and his coauthors for their efforts to increase our knowl- 
edge about a very troublesome clinical problem. 
Dr. Andrew C. Stanley. Yes, we did perform the growth 
factor analysis on normal cells as well as wound cells. They did 
respond to a greater magnitude than the wound fibroblasts 
themselves, o it seems like the response to growth factors is 
somewhat blunted. We made some analogies towards enes- 
cence in our work, and basically the Hayflick model makes 
analogous associations between senescence and extreme ag- 
ing. It has been shown by a lot of the dermatologic l terature 
that as cells age they become less responsive to growth factors 
as a result of fewer receptors at the cellular level and poor 
intake of the receptor cytokine complex. So yes, we did have 
better esponse with our normal fibroblasts, and yes, it seems 
like the normal fibroblasts respond better than the wound 
fibroblasts in cell per cell basis. 
As far as insight into the reason why the growth factors 
have not been successfial, a lot of investigators have postu- 
lated as to the delivery system being inadequate and met- 
alloproteinases at the wound level doing a number on the 
proteins as they're delivered, whatever mode they're deliv- 
ered in. I think that that is the best hing that our study can 
say. I don't have anything to back this up at this point, but 
I think that growth factors are probably not the best way to 
treat these ulcers in the long term. But I think what our 
study will direct us towards doing is finding what at the 
wound level is causing the changes and maybe that can be 
blocked. 
There is a group down in Miami that's actually using 
neonatal fibroblasts and neonatal keratinocytes in a graft- 
ing fashion to graft over the venous ulcers themselves. I 
think the reason why they are having some success with 
that is that they are putting, obviously, a much younger 
group of cells down on the ulcers, and it takes a lot longer 
for those cells to go to a senescent s age in which they 
become inadequate. So we'll see how that study goes. 
Dr. Harry Schanzer. I want to congratulate Dr. Stan- 
ley and his group for this excellent paper. I think that this 
model has a lot of potential for understanding the biology 
and the behavior of the venous ulcers in the clinical setting 
and in evaluating the usefulness of growth factors. Finally, 
it takes it out from the area of voodoo medicine. 
I am sure that everybody here agrees with me that 
there are ulcers that heal very easily and other ulcers that 
cannot be made to heal. I never have been able to really 
understand why this happens. The reason is not related to 
the severity of chronic venous tasis or to local factors. I 
would like to know whether after your studies you have got 
any information, or have you correlated this behavior clin- 
ically with your findings in this model? 
Dr. Stanley. Unfortunately, like I mentioned earlier, 
the more we find out about it the more questions arise. But 
it seems that the folks who have had longer-standing dis- 
ease or recurrent ulcers, as you'd find in clinical practice, 
are the hardest ones to heal. Those are the ones that have 
the poorest response to growth factors and have the big- 
gest differential between the wound and normal fibro- 
blasts. 
Dr. Michael A. Golden (Philadelphia, Pa.). I want to 
congratulate Dr. Stanley and his coauthors for their excel- 
lent work. Did you observe any differences in the behavior 
of the cells with passage number in culture? 
Also, as wound healing involves contraction and cellu- 
lar migration, have you looked at cellular migration in 
addition to proliferation i  terms of the behavior of these 
different cell types? 
Dr. Stanley. I'll answer your last question first because 
it's the easiest. No, we haven't, but we plan on looking at 
migration. 
We did all of our experimentation on passage 2 cells. 
What we ended up doing was the explant echniques, as 
you know, generate a passage 1 cell. We split those up 
into two groups for our second pass; we experimented 
on one and froze the others. We found that freezing the 
cells makes them relatively stable. I repeated a lot of the 
experiments on the cells that are frozen, and the results 
were similar. I could show you grafts of that, too. So we 
have a library that we can continue doing work on the 
same passage cells, so we haven't really had to take our 
cells out a number of passages, o I can't tell you exactly 
what they do. 
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Dr. Anton N. Sidawy (Washington, D.C.). I think 
these data may be very pertinent clinically. Because you 
found that there is a difference in proliferation between 
fibroblasts cultured from slowly healing ulcers and normal 
skin fibroblasts, do you think that growth factors applied at 
fresh tissue after r moval of a slowly healing ulcer would 
have a better chance of stimulating healing. 
I agree with Dr. Golden that the number of passage is
important. Apparently ou have been using second-pas- 
sage cells. I am wondering if you use cells from number five 
or six passages whether you will see a different response and 
whether then the environmental f ctors tha~ had caused 
these cells to be senescent and lose their effect. 
Dr. Stanley. I'll answer your last question first. It's not 
something that we thought about, but it sounds like a 
good idea to go ahead with that. Our initial feeling after 
talking with a lot of the investigators who had some expe- 
rience in this area was that the lowest passage we could 
work with would be best because it would most closely 
approximate he wound environment itself, even though 
we took them out of their environment and put them in 
normal media. So that is something we should look into. 
Dr. Sidawy. As I said, because we do not know why 
cells cultured from ulcers react differently, some local fac- 
tors may cause these cells to become senescent. These 
factors are not present in culture conditions, o after mul- 
tiple passages the cells' growth pattern may normalize. 
Dr. Stanley. As to your first question, we don't  
know exactly what is causing these changes in the cells. 
Venous hypertension is something that a lot of people 
have postulated along the way, and we're not sure 
whether these changes that we're seeing at the ulcer 
border--all these biopsies were done at the ulcer bor- 
der -are  seen in the normal skin, or what we'd call 
normal skin, or in the tissue around it that's also subject 
to venous hypertension. So I 'm not sure that by excising 
the ulcers and using growth factors in that area that 
would be adequate, and I wouldn't suggest doing it 
until we have more information as to the mechanisms 
and what's causing the changes. 
Dr. Steven G. Friedman (Manhasset, N.Y.). I just 
wanted to congratulate Dr. Stanley. He's this year's Amer- 
ican Venous Forum's Jobst Research Recipient for his 
work on the fibroblasts, o we look forward to seeing the 
results of this over the next few years. 
I have more of a comment than a question in relation 
to what may be mediating some of these responses. As you 
know from some of the data we presented this year, it may 
be more of the cellular infiltrate that may be mediating 
some of these responses. A  you know, mast cells seem to 
be playing more of a predominant role now. They seem to 
be the gatekeeper, if you will, as to what causes the macro- 
phages and the fibroblasts to function properly. Some of 
the data that we have seen in my laboratory that TGF-J31 is 
a very big player in this and that the proliferative layer in 
normal epidermal cells have a lot of TGF-I31 and that 
seems to switch to the fibroblasts in the disease state. So 
something is causing these cells to become unresponsive. 
TGF-I31 may be playing an inhibitor ole at the epidermal 
growth layer, and then the fibroblasts may be causing them 
to do something else. So I think you're on the right track. 
I encourage you to continue this research and I'll look 
forward to some of the data. 
Dr. Stanley. Thank you very much. 
